Kurtis Hull
Internal Medicine · Indianapolis, INNPI 1255350674
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 280 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,541 and has fallen 98.2% since, to $28 in 2023.
Across 280 payments — averaging $12.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$757
- Novo Nordisk$588
- Amarin Pharma, Inc.$353
- GSK$287
- AstraZeneca$236
- Boehringer Ingelheim$232
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,60599%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $757 |
| Novo Nordisk | 48 | $588 |
| Amarin Pharma, Inc. | 24 | $353 |
| GSK | 22 | $287 |
| AstraZeneca | 13 | $236 |
| Boehringer Ingelheim | 21 | $232 |
| Amgen(2 entities) | 9 | $150 |
| Merck | 9 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $118 |
| Lilly USA, LLC | 8 | $111 |
| Johnson & Johnson | 8 | $106 |
| Novartis | 7 | $90 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $81 |
| Pfizer | 5 | $76 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Nestle Healthcare Nutrition Inc. | 3 | $48 |
| Jazz Pharmaceuticals Inc. | 3 | $46 |
| Ironwood Pharmaceuticals, Inc | 2 | $32 |
| Eisai Inc. | 2 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Biogen | 2 | $24 |
| Astellas Pharma US Inc | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$3,628 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XeljanzTofacitinib Citrate | 11 | $61,300 |
| Omeprazole | 28 | $341 |
| Ezetimibe | 11 | $248 |
| Atorvastatin Calcium | 18 | $206 |
| Levothyroxine Sodium | 22 | $190 |
| Montelukast Sodium | 15 | $174 |
| Glimepiride | 13 | $147 |
| Rosuvastatin Calcium | 21 | $136 |
| Metformin Hcl | 13 | $27 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerXeljanz | $76 | $61,30011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Indianapolis
- Raj VuppalanchiIndianapolis$279K
- Napoleon MamintaIndianapolis$116K
- Allon FriedmanIndianapolis$111K
- John AyresIndianapolis$107K
- Awaneesh KumarIndianapolis$68K
- Justin FieldIndianapolis$49K
- Misty ShieldsIndianapolis$39K
- Volodymyr OliynykIndianapolis$38K
- Sapan BhutaIndianapolis$30K
- Azizullah BeranIndianapolis$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.